Novartis (NVS) has released an update. Novartis has reported a robust third quarter in 2024, showcasing a 10% increase in net sales and a 20% rise in core operating income, driven by strong ...

Novartis NOVN-1.67%decrease; red down pointing triangle raised its guidance for the third time this year after higher third-quarter results topped expectations, boosted by revenue from its ...

Novartis expects to increase its annual sales by least 5% per year in the coming years, CEO Vas Narasimhan said in an ...

In its latest financial report, Monte Rosa Therapeutics has announced a significant partnership with Novartis, alongside progress in its pipeline of drug candidates. The partnership involves a global ...

Oct 16 (Reuters) - Novartis (NOVN.S), opens new tab has lost a bid to keep a generic version of its top-selling heart failure drug Entresto off the U.S. market by blocking regulators from ...

Truist highlights Novartis' strong balance sheet, which enables further bolt-on deals and share buybacks. Recent transactions primarily involve deals in the sub-$1 billion range, along with a few ...

Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights Novartis aims to enhance Pluvicto's market presence while exploring growth in multiple ...

Operator Good morning and good afternoon, and welcome to the Novartis Q3 2024 results release conference call and live ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Novartis has a long way to go to make its twice-yearly cholesterol-lowering drug Leqvio the multi-billion-dollar blockbuster it is predicting – but took another step along that road today.

LONDON — It hasn’t even been a year since Pfizer closed its $43 billion acquisition of Seagen — one of the biggest biopharma deals in years — but David Epstein, who was CEO of Seagen, is back.

Novartis has terminated a phase 2 trial of its SMURF1 inhibitor LTP001 in idiopathic pulmonary fibrosis (IPF) but will continue to advance the candidate in another indication. The Swiss drugmaker ...